Bristol Myers Squibb vs Pfizer (BMY vs PFE)
Bristol Myers Squibb trades at 13.2x earnings vs 40.1x for Pfizer; Bristol Myers Squibb grows sales faster (+6.9% vs -0.4%). Debt and dividend, Nov 2026.
Quick answer
On today's data (November 19, 2026): Bristol Myers Squibb looks cheaper on P/E: 13.2x against 40.1x for Pfizer. Bristol Myers Squibb grows faster: sales +6.9% against -0.4% for Pfizer in the latest quarter. Bristol Myers Squibb has the better net margin: 18.5% against 6.3% for Pfizer.
This is a snapshot of the numbers, not a recommendation to buy or sell.
Your first analysis is free with a free account, no card.
Short answer
On P/E as of November 19, 2026, Pfizer is the more expensive of the two: it trades at 40.1x its annual earnings against 13.2x for Bristol Myers Squibb. Bristol Myers Squibb sells prescription drugs in a single segment. Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev. What helps read that gap: Pfizer sales -0.4% against +6.9% for Bristol Myers Squibb in the latest quarter; net margin 6.3% against 18.5%; net debt for Pfizer: 2.0x EBITDA against 1.8x EBITDA. A higher P/E is not by itself a buy or a sell signal: it is a snapshot of today.
Bristol Myers Squibb (BMY) and Pfizer (PFE) compete in healthcare and pharma. Here are Bristol Myers Squibb and Pfizer side by side with their real figures as of November 19, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Bristol Myers Squibb or Pfizer.
Bristol Myers Squibb vs Pfizer: the figures
| Figure | Bristol Myers Squibb | Pfizer |
|---|---|---|
| Share price | $59.56 (November 18, 2026) | $28.06 (November 18, 2026) |
| Market cap | $121.7 billion | $159.9 billion |
| P/E (TTM) | 13.2x | 40.1x |
| Forward P/E | 8.9x | 9.5x |
| Revenue growth (quarter) | +6.9% | -0.4% |
| Net margin (TTM) | 18.5% | 6.3% |
| Net debt / EBITDA | 1.8x | 2.0x |
| Dividend yield | 4.23% | 6.13% |
| Beta | 0.19 | 0.30 |
Bristol Myers Squibb and Pfizer figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 19, 2026; N/A means that Bristol Myers Squibb or Pfizer figure is not available, and we never estimate it.
3 key differences between Bristol Myers Squibb and Pfizer
- Valuation: Pfizer trades at 40.1x its annual earnings and Bristol Myers Squibb at 13.2x; the market pays more for each dollar of Pfizer profit, usually because it expects more growth.
- Profitability: for every 100 of sales, Bristol Myers Squibb keeps 18.5 as net profit and Pfizer keeps 6.3.
- Dividend: Pfizer yields 6.13% at today's price and Bristol Myers Squibb yields 4.23%.
Bristol Myers Squibb or Pfizer: which fits your profile
- If you want growth: Bristol Myers Squibb is growing faster today, with sales +6.9% against -0.4% for Pfizer and also trades on a lower P/E (13.2x against 40.1x). Investors who prioritise growth usually accept more volatility; the P/E only shows what you pay today for each unit of the last 12 months' earnings.
- If you want income (dividends): Pfizer pays the higher dividend relative to its price.
- If you prefer caution: Bristol Myers Squibb has less debt relative to its profit, which usually gives more room in a bad year.
- If price is what matters most to you: Bristol Myers Squibb trades on the lower P/E; check first whether that is an opportunity or a sign of a business that grows less.
Neither Bristol Myers Squibb nor Pfizer wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.
Verdict: Bristol Myers Squibb or Pfizer?
Of the 6 comparable figures in the table, Bristol Myers Squibb stands out on 5 (sales growth, net margin, lower P/E, less debt over EBITDA and lower volatility (beta)) and Pfizer stands out on 1 (dividend yield). That does not name a winner between Bristol Myers Squibb and Pfizer: the table is a snapshot of today, not a forecast.
Keep reading free.
Create your free account to continue reading “Bristol Myers Squibb vs Pfizer (BMY vs PFE)”.
No card required
Bristol Myers Squibb vs Pfizer by dimension
Strategy
Bristol Myers Squibb operates in healthcare and pharma and Pfizer in healthcare and pharma, so they only fight for the same customer when the sector overlaps. By stock-market size, Pfizer is the larger of the two.
Products and AI
Bristol Myers Squibb and Pfizer sell different things: Bristol Myers Squibb sells prescription drugs in a single segment. And for Pfizer: Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev.
Margins
Bristol Myers Squibb is more profitable: it keeps 18.5 of every 100 it sells, against 6.3 for Pfizer.
Valuation
Pfizer trades at the higher P/E (40.1x against 13.2x for Bristol Myers Squibb). A higher P/E is only justified if earnings grow faster.
Risks
Pfizer is the more volatile: beta 0.30 against 0.19 for Bristol Myers Squibb.
Competitors
Other companies investors compare Bristol Myers Squibb and Pfizer with: CVS Health, Danaher, Thermo Fisher, UnitedHealth. CVS Health · Danaher · Thermo Fisher · UnitedHealth
How Bristol Myers Squibb and Pfizer make money
Bristol Myers Squibb (BMY)
Bristol Myers Squibb sells prescription drugs in a single segment. Its biggest products are Eliquis, a blood thinner marketed with Pfizer, and Opdivo, a cancer immunotherapy, along with Revlimid, Pomalyst, Breyanzi, Camzyos and the schizophrenia drug Cobenfy. The United States generates most of its revenue. Full Bristol Myers Squibb analysis.
Pfizer (PFE)
Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev. The U.S. is its biggest market. Full Pfizer analysis.
Frequently asked questions: Bristol Myers Squibb vs Pfizer
What is the difference between Bristol Myers Squibb and Pfizer?
Bristol Myers Squibb sells prescription drugs in a single segment. Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev. Both are in healthcare and pharma. As of November 19, 2026: P/E 13.2 vs 40.1; net margin 18% vs 6% (Bristol Myers Squibb vs Pfizer).
Is Bristol Myers Squibb or Pfizer the better stock?
Choosing between Bristol Myers Squibb and Pfizer depends on what you are looking for. Bristol Myers Squibb is growing faster right now, and Bristol Myers Squibb trades on the lower P/E. Fintols does not tell you whether to buy Bristol Myers Squibb or Pfizer: it shows you the differences so you can decide.
Which pays a higher dividend, Bristol Myers Squibb or Pfizer?
As of November 19, 2026, Pfizer yields 6.13% and Bristol Myers Squibb yields 4.23%. Also check how much of their profit Bristol Myers Squibb and Pfizer pay out: if it is more than they earn, it cannot last.
Which is more expensive, Bristol Myers Squibb or Pfizer?
On P/E, Pfizer (40.1x) is more expensive than Bristol Myers Squibb (13.2x) as of November 19, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.
Which is more profitable, Bristol Myers Squibb or Pfizer?
On net margin, Bristol Myers Squibb (18.5%) keeps more of every 100 it sells than Pfizer (6.3%), as of November 19, 2026.
Which has more debt, Bristol Myers Squibb or Pfizer?
As of November 19, 2026, Pfizer owes 2.0x its EBITDA and Bristol Myers Squibb owes 1.8x its EBITDA (net debt over EBITDA).
Can I own both Bristol Myers Squibb and Pfizer?
Yes. Many people spread their money across several companies, such as Bristol Myers Squibb and Pfizer, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Bristol Myers Squibb or Pfizer.
To go deeper: Does Bristol Myers Squibb pay a dividend? and Does Pfizer pay a dividend?.
Related comparisons for Bristol Myers Squibb and Pfizer
- Bristol Myers Squibb vs CVS Health
- Bristol Myers Squibb vs Danaher
- Bristol Myers Squibb vs Gilead
- Bristol Myers Squibb vs Eli Lilly
More companies like Bristol Myers Squibb and Pfizer: healthcare and pharma stocks. Educational content about Bristol Myers Squibb and Pfizer, not investment advice.
Full analyses: Bristol Myers Squibb and Pfizer. Machine-readable summary: llms.txt.
Your first analysis is free with a free account, no card.
Your own analysis of Bristol Myers Squibb or Pfizer.
Create a free account and run your first full analysis in a minute. No card needed.
- How it makes money
- Valuation scenarios
- What could go wrong
First full analysis free · No card